cycD1/CCND1 Cancer Research Results

cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
5174- Ash,    Withaferin A is a potent inhibitor of angiogenesis
- in-vitro, Nor, HUVECs
Inflam↓, *TumCP↓, cycD1/CCND1↓, NF-kB↓, angioG↓,
2474- Ba,    Anticancer properties of baicalein: a review
- Review, Var, NA - in-vitro, Nor, BV2
ROS⇅, ROS↑, ER Stress↑, Ca+2↑, Apoptosis↑, eff↑, DR5↑, 12LOX↓, Cyt‑c↑, Casp7↑, Casp9↑, Casp3↑, cl‑PARP↑, TumCCA↑, cycE/CCNE↑, CDK4↓, cycD1/CCND1↓, VEGF↓, cMyc↓, Hif1a↓, NF-kB↓, BioEnh↑, BioEnh↑, P450↓, *Hif1a↓, *iNOS↓, *COX2↓, *VEGF↓, *ROS↓, *PI3K↓, *Akt↓,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
5150- GamB,    Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway
- in-vitro, CLL, KBM-5 - in-vitro, Nor, HEK293
Apoptosis↑, ChemoSen↑, IAP1↓, IAP2↓, Bcl-2↓, Bcl-xL↓, TRAF1↓, cycD1/CCND1↓, cMyc↓, COX2↓, MMP9↓, angioG↓, VEGF↓, NF-kB↓, eff↓,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, eff↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,
5123- Sal,    Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells
- in-vitro, BC, MCF-7 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, HEK293
Wnt↓, β-catenin/ZEB1↓, mTORC1↓, GSK‐3β↑, cycD1/CCND1↓, survivin↓, LRP6↓, TumCG↓, Apoptosis↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 3,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   MEK↓, 1,   MMP↓, 2,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   AMPK↑, 1,   cMyc↓, 2,   Glycolysis↓, 1,   LDH↓, 1,   p‑S6K↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 5,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp3↑, 4,   Casp7↑, 1,   Casp9↑, 3,   Cyt‑c↑, 2,   DR5↑, 1,   IAP1↓, 1,   IAP2↓, 1,   MAPK↓, 1,   p27↑, 1,   p38↓, 1,   survivin↓, 1,   Telomerase↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 1,   cycE/CCNE↑, 1,   P21↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD24↓, 1,   CD44↓, 1,   CSCs↓, 1,   Diff↓, 1,   EMT↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   GSK‐3β↑, 1,   LRP6↓, 1,   mTOR↓, 1,   mTORC1↓, 1,   p‑mTORC1↓, 1,   n-MYC↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   PTEN↑, 1,   SOX2↓, 1,   STAT3↓, 1,   TumCG↓, 3,   Wnt↓, 1,  

Migration ⓘ

Ca+2↑, 3,   E-cadherin↑, 1,   Ki-67↓, 1,   MMP2↓, 3,   MMP7↓, 1,   MMP9↓, 4,   TIMP1↑, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumMeta↓, 1,   Twist↓, 1,   uPA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 1,   Hif1a↓, 3,   VEGF↓, 4,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   COX2↓, 2,   CXCR4↓, 1,   IL6↓, 1,   Inflam↓, 2,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 5,   PGE2↓, 2,   TRAF1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioEnh↑, 2,   ChemoSen↑, 3,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   eff↓, 1,   eff↑, 5,   eff↝, 1,   P450↓, 1,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   IL6↓, 1,   Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 110

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

PPARγ↓, 1,  

Cell Death ⓘ

Akt↓, 1,   iNOS↓, 1,   MAPK↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 1,   Inflam↑, 1,   PGE2↓, 1,   TLR2↓, 1,   TLR4↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   neuroP↑, 2,   toxicity↓, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 22

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
1 Ashwagandha(Withaferin A)
1 Baicalein
1 Berberine
1 Gambogic Acid
1 Magnolol
1 Quercetin
1 salinomycin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page